{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:08:19Z","timestamp":1793333299564,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.gassur.2026.102532","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:22:02Z","timestamp":1784992922000},"page":"102532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world impact of first-line nivolumab plus chemotherapy on conversion surgery and survival outcomes in advanced gastric and esophagogastric junction cancer: a propensity score-matched analysis"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9531-5157","authenticated-orcid":false,"given":"Akihiko","family":"Sano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Kuriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhisa","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kumakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiharu","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Shirabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.gassur.2026.102532_bib1","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/ags3.12835","article-title":"Incidence, mortality, survival, and treatment statistics of cancers in digestive organs-Japanese cancer statistics 2024","volume":"8","author":"Higashi","year":"2024","journal-title":"Ann Gastroenterol Surg"},{"issue":"1","key":"10.1016\/j.gassur.2026.102532_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","journal-title":"Gastric Cancer"},{"issue":"10294","key":"10.1016\/j.gassur.2026.102532_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.gassur.2026.102532_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.gassur.2026.102532_bib5","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102532_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.gassur.2026.102532_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ags3.12515","article-title":"International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1)","volume":"6","author":"Yoshida","year":"2021","journal-title":"Ann Gastroenterol Surg"},{"issue":"1","key":"10.1016\/j.gassur.2026.102532_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12876-024-03155-5","article-title":"Safety and feasibility of minimally invasive gastrectomy following preoperative chemotherapy for highly advanced gastric cancer","volume":"24","author":"Tanaka","year":"2024","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"10.1016\/j.gassur.2026.102532_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108582","article-title":"Surgical treatment for liver metastasis from gastric cancer: a systematic review and meta-analysis of long-term outcomes and prognostic factors","volume":"50","author":"Takahashi","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102532_bib10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/jjco\/hyae174","article-title":"Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study)","volume":"55","author":"Kita","year":"2025","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.gassur.2026.102532_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.gassur.2026.102532_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","article-title":"Japanese classification of gastric carcinoma: 3rd English edition","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.gassur.2026.102532_bib13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"10.1016\/j.gassur.2026.102532_bib14","doi-asserted-by":"crossref","first-page":"9023","DOI":"10.1245\/s10434-024-16161-4","article-title":"Conversion surgery after chemotherapy plus nivolumab as the first-line treatment for unresectable advanced or recurrent gastric cancer and a biomarker study using the Gustave Roussy immune score: a multicenter study","volume":"31","author":"Nakazawa","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.gassur.2026.102532_bib15","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1097\/JS9.0000000000000738","article-title":"Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer","volume":"109","author":"Liang","year":"2023","journal-title":"Int J Surg"},{"issue":"2","key":"10.1016\/j.gassur.2026.102532_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107314","article-title":"Treatment strategy for successful conversion surgery in clinical stage IVB gastric cancer","volume":"50","author":"Hojo","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.gassur.2026.102532_bib17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ags3.12738","article-title":"Clinical impact of very early recurrence after conversion surgery for stage IV gastric cancer","volume":"8","author":"Morito","year":"2023","journal-title":"Ann Gastroenterol Surg"},{"issue":"3","key":"10.1016\/j.gassur.2026.102532_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ags3.12778","article-title":"Prognostic factors of conversion surgery for stage IV gastric cancer: a multi-institutional retrospective analysis","volume":"8","author":"Takeno","year":"2024","journal-title":"Ann Gastroenterol Surg"},{"issue":"3","key":"10.1016\/j.gassur.2026.102532_bib19","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10120-020-01137-6","article-title":"Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective study","volume":"24","author":"Yamaguchi","year":"2021","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.gassur.2026.102532_bib20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1245\/s10434-019-07697-x","article-title":"Efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology (CY1) or localized peritoneum metastasis (P1a): a multicenter retrospective study","volume":"27","author":"Yamaguchi","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102532_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/SLA.0000000000001346","article-title":"Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01)","volume":"263","author":"Kim","year":"2016","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.gassur.2026.102532_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S2468-1253(19)30332-2","article-title":"Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial","volume":"5","author":"Katai","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.gassur.2026.102532_bib23","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1007\/s00268-015-3160-z","article-title":"A multi-institutional, prospective, phase II feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901)","volume":"39","author":"Inaki","year":"2015","journal-title":"World J Surg"},{"issue":"6","key":"10.1016\/j.gassur.2026.102532_bib24","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/SLA.0000000000003217","article-title":"Short-term outcomes of a multicenter randomized controlled trial comparing laparoscopic distal gastrectomy with D2 lymphadenectomy to open distal gastrectomy for locally advanced gastric cancer (KLASS-02-RCT)","volume":"270","author":"Lee","year":"2019","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.gassur.2026.102532_bib25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s11605-018-3937-0","article-title":"The safety and feasibility of single-port laparoscopic gastrectomy for advanced gastric cancer","volume":"23","author":"Omori","year":"2019","journal-title":"J Gastrointest Surg"},{"issue":"20","key":"10.1016\/j.gassur.2026.102532_bib26","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1001\/jama.2019.5359","article-title":"Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial","volume":"321","author":"Yu","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.gassur.2026.102532_bib27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ags3.12343","article-title":"Minimally invasive surgery is feasible after preoperative chemotherapy for stage IV gastric cancer","volume":"4","author":"Yamamoto","year":"2020","journal-title":"Ann Gastroenterol Surg"},{"issue":"10389","key":"10.1016\/j.gassur.2026.102532_bib28","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.gassur.2026.102532_bib29","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.gassur.2026.102532_bib30","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102532_bib31","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"issue":"10418","key":"10.1016\/j.gassur.2026.102532_bib32","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X26002131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X26002131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:29:54Z","timestamp":1790774994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X26002131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1091255X26002131"],"URL":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102532","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world impact of first-line nivolumab plus chemotherapy on conversion surgery and survival outcomes in advanced gastric and esophagogastric junction cancer: a propensity score-matched analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society for Surgery of the Alimentary Tract. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102532"}}